Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma

Core Viewpoint - Ipsen has received a favorable ruling from the ICC Arbitral Tribunal, confirming its rights to clinical stage toxin programs in aesthetics and dismissing Galderma's claims related to the termination of an R&D agreement [1][2] Group 1: Legal and Regulatory Developments - The ICC Tribunal's decision supports Ipsen's leadership in neuroscience research and development, allowing the company to focus on maximizing the value of its product IPN10200 [2] - The ruling affirms Ipsen's full rights to its clinical stage toxin programs, which is crucial for its ongoing development efforts [1] Group 2: Product Development - IPN10200 is a first-in-class recombinant molecule designed for enhanced receptor affinity and internalization, showing a longer duration of effect [3] - The molecule is currently being evaluated in four Phase II trials for both aesthetic and therapeutic indications, indicating a robust development pipeline [3] Group 3: Clinical Trials - The LANTIC trial, which includes 727 participants, is assessing the safety and efficacy of IPN10200 for treating moderate to severe upper facial lines [4] - The trial consists of multiple stages, with Stage 1 focusing on dose finding and escalation for glabellar lines, and subsequent stages evaluating efficacy against placebo and Dysport [4] Group 4: Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [5] - The company operates in over 40 countries and partners globally to deliver medicines to more than 100 countries [5]